Fibromyalgia ||| S:0 E:12 ||| NNP
:  ||| S:12 E:14 ||| :
an  ||| S:14 E:17 ||| DT
overview  ||| S:17 E:26 ||| JJ
Fibromyalgia  ||| S:26 E:39 ||| NNP
is  ||| S:39 E:42 ||| VBZ
the  ||| S:42 E:46 ||| DT
diagnosis  ||| S:46 E:56 ||| NN
given  ||| S:56 E:62 ||| VBN
to  ||| S:62 E:65 ||| TO
individuals  ||| S:65 E:77 ||| NNS
with  ||| S:77 E:82 ||| IN
chronic  ||| S:82 E:90 ||| JJ
widespread  ||| S:90 E:101 ||| JJ
musculoskeletal  ||| S:101 E:117 ||| JJ
pain  ||| S:117 E:122 ||| NN
for  ||| S:122 E:126 ||| IN
which  ||| S:126 E:132 ||| WDT
no  ||| S:132 E:135 ||| DT
alternative  ||| S:135 E:147 ||| JJ
cause ||| S:147 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
such  ||| S:154 E:159 ||| JJ
as  ||| S:159 E:162 ||| IN
tissue  ||| S:162 E:169 ||| NN
inflammation  ||| S:169 E:182 ||| NNS
or  ||| S:182 E:185 ||| CC
damage ||| S:185 E:191 ||| NN
,  ||| S:191 E:193 ||| ,
can  ||| S:193 E:197 ||| MD
be  ||| S:197 E:200 ||| VB
identified ||| S:200 E:210 ||| VBN
.  ||| S:210 E:212 ||| .
Fibromyalgia  ||| S:212 E:225 ||| NNP
is  ||| S:225 E:228 ||| VBZ
now  ||| S:228 E:232 ||| RB
believed  ||| S:232 E:241 ||| VBN
to  ||| S:241 E:244 ||| TO
be ||| S:244 E:246 ||| VB
,  ||| S:246 E:248 ||| ,
at  ||| S:248 E:251 ||| IN
least  ||| S:251 E:257 ||| JJS
in  ||| S:257 E:260 ||| IN
part ||| S:260 E:264 ||| NN
,  ||| S:264 E:266 ||| ,
a  ||| S:266 E:268 ||| DT
disorder  ||| S:268 E:277 ||| NN
of  ||| S:277 E:280 ||| IN
central  ||| S:280 E:288 ||| JJ
pain  ||| S:288 E:293 ||| NN
processing  ||| S:293 E:304 ||| NN
that  ||| S:304 E:309 ||| WDT
produces  ||| S:309 E:318 ||| VBZ
heightened  ||| S:318 E:329 ||| VBN
responses  ||| S:329 E:339 ||| NNS
to  ||| S:339 E:342 ||| TO
painful  ||| S:342 E:350 ||| JJ
stimuli  ||| S:350 E:358 ||| NNS
( ||| S:358 E:359 ||| -LRB-
hyperalgesia ||| S:359 E:371 ||| LS
)  ||| S:371 E:373 ||| -RRB-
and  ||| S:373 E:377 ||| CC
painful  ||| S:377 E:385 ||| JJ
responses  ||| S:385 E:395 ||| NNS
to  ||| S:395 E:398 ||| TO
nonpainful  ||| S:398 E:409 ||| VB
stimuli  ||| S:409 E:417 ||| NNS
( ||| S:417 E:418 ||| -LRB-
allodynia ||| S:418 E:427 ||| LS
) ||| S:427 E:428 ||| -RRB-
.  ||| S:428 E:430 ||| .
Aberrations  ||| S:430 E:442 ||| NNP
in  ||| S:442 E:445 ||| IN
central  ||| S:445 E:453 ||| JJ
pain  ||| S:453 E:458 ||| NN
processing  ||| S:458 E:469 ||| NN
may  ||| S:469 E:473 ||| MD
also  ||| S:473 E:478 ||| RB
be  ||| S:478 E:481 ||| VB
partly  ||| S:481 E:488 ||| RB
responsible  ||| S:488 E:500 ||| JJ
for  ||| S:500 E:504 ||| IN
symptoms  ||| S:504 E:513 ||| NNS
experienced  ||| S:513 E:525 ||| VBN
in  ||| S:525 E:528 ||| IN
several  ||| S:528 E:536 ||| JJ
chronic  ||| S:536 E:544 ||| JJ
pain  ||| S:544 E:549 ||| NN
disorders  ||| S:549 E:559 ||| NNS
that  ||| S:559 E:564 ||| IN
coaggregate  ||| S:564 E:576 ||| NN
with  ||| S:576 E:581 ||| IN
fibromyalgia ||| S:581 E:593 ||| NN
,  ||| S:593 E:595 ||| ,
which  ||| S:595 E:601 ||| WDT
is  ||| S:601 E:604 ||| VBZ
itself  ||| S:604 E:611 ||| PRP
a  ||| S:611 E:613 ||| DT
product  ||| S:613 E:621 ||| NN
of  ||| S:621 E:624 ||| IN
genetic  ||| S:624 E:632 ||| JJ
and  ||| S:632 E:636 ||| CC
environmental  ||| S:636 E:650 ||| JJ
factors ||| S:650 E:657 ||| NNS
.  ||| S:657 E:659 ||| .
Thus ||| S:659 E:663 ||| RB
,  ||| S:663 E:665 ||| ,
aberrational  ||| S:665 E:678 ||| JJ
central  ||| S:678 E:686 ||| JJ
pain  ||| S:686 E:691 ||| NN
processing  ||| S:691 E:702 ||| NN
is  ||| S:702 E:705 ||| VBZ
implicated  ||| S:705 E:716 ||| VBN
in  ||| S:716 E:719 ||| IN
irritable  ||| S:719 E:729 ||| JJ
bowel  ||| S:729 E:735 ||| JJ
syndrome ||| S:735 E:743 ||| NN
,  ||| S:743 E:745 ||| ,
temporomandibular  ||| S:745 E:763 ||| JJ
disorder ||| S:763 E:771 ||| NN
,  ||| S:771 E:773 ||| ,
chronic  ||| S:773 E:781 ||| JJ
low  ||| S:781 E:785 ||| JJ
back  ||| S:785 E:790 ||| JJ
pain ||| S:790 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
and  ||| S:796 E:800 ||| CC
certain  ||| S:800 E:808 ||| JJ
other  ||| S:808 E:814 ||| JJ
chronic  ||| S:814 E:822 ||| JJ
pain  ||| S:822 E:827 ||| NN
disorders ||| S:827 E:836 ||| NNS
.  ||| S:836 E:838 ||| .
Fibromyalgia  ||| S:838 E:851 ||| NNP
and  ||| S:851 E:855 ||| CC
related  ||| S:855 E:863 ||| JJ
disorders  ||| S:863 E:873 ||| NNS
appear  ||| S:873 E:880 ||| VBP
to  ||| S:880 E:883 ||| TO
reflect  ||| S:883 E:891 ||| VB
deficiencies  ||| S:891 E:904 ||| NNS
in  ||| S:904 E:907 ||| IN
serotonergic  ||| S:907 E:920 ||| NN
and  ||| S:920 E:924 ||| CC
noradrenergic ||| S:924 E:937 ||| NN
,  ||| S:937 E:939 ||| ,
but  ||| S:939 E:943 ||| CC
not  ||| S:943 E:947 ||| RB
opioidergic ||| S:947 E:958 ||| JJ
,  ||| S:958 E:960 ||| ,
transmission  ||| S:960 E:973 ||| NN
in  ||| S:973 E:976 ||| IN
the  ||| S:976 E:980 ||| DT
central  ||| S:980 E:988 ||| JJ
nervous  ||| S:988 E:996 ||| JJ
system ||| S:996 E:1002 ||| NN
.  ||| S:1002 E:1004 ||| .
The  ||| S:1004 E:1008 ||| DT
heightened  ||| S:1008 E:1019 ||| JJ
state  ||| S:1019 E:1025 ||| NN
of  ||| S:1025 E:1028 ||| IN
pain  ||| S:1028 E:1033 ||| NN
transmission  ||| S:1033 E:1046 ||| NN
may  ||| S:1046 E:1050 ||| MD
also  ||| S:1050 E:1055 ||| RB
be  ||| S:1055 E:1058 ||| VB
owing  ||| S:1058 E:1064 ||| VBG
to  ||| S:1064 E:1067 ||| TO
increases  ||| S:1067 E:1077 ||| NNS
in  ||| S:1077 E:1080 ||| IN
pronociceptive  ||| S:1080 E:1095 ||| JJ
neurotransmitters  ||| S:1095 E:1113 ||| JJ
such  ||| S:1113 E:1118 ||| JJ
as  ||| S:1118 E:1121 ||| IN
glutamate  ||| S:1121 E:1131 ||| NN
and  ||| S:1131 E:1135 ||| CC
substance  ||| S:1135 E:1145 ||| NN
P.  ||| S:1145 E:1148 ||| NNP
In  ||| S:1148 E:1151 ||| IN
some  ||| S:1151 E:1156 ||| DT
cases ||| S:1156 E:1161 ||| NNS
,  ||| S:1161 E:1163 ||| ,
psychological  ||| S:1163 E:1177 ||| JJ
and  ||| S:1177 E:1181 ||| CC
behavioral  ||| S:1181 E:1192 ||| JJ
factors  ||| S:1192 E:1200 ||| NNS
are  ||| S:1200 E:1204 ||| VBP
also  ||| S:1204 E:1209 ||| RB
in  ||| S:1209 E:1212 ||| IN
play ||| S:1212 E:1216 ||| NN
.  ||| S:1216 E:1218 ||| .
Although  ||| S:1218 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
overlapping  ||| S:1231 E:1243 ||| JJ
symptomatology  ||| S:1243 E:1258 ||| NN
between  ||| S:1258 E:1266 ||| IN
fibromyalgia  ||| S:1266 E:1279 ||| NN
and  ||| S:1279 E:1283 ||| CC
related  ||| S:1283 E:1291 ||| JJ
disorders  ||| S:1291 E:1301 ||| NNS
may  ||| S:1301 E:1305 ||| MD
present  ||| S:1305 E:1313 ||| VB
diagnostic  ||| S:1313 E:1324 ||| JJ
challenges ||| S:1324 E:1334 ||| NNS
,  ||| S:1334 E:1336 ||| ,
proper  ||| S:1336 E:1343 ||| JJ
examination  ||| S:1343 E:1355 ||| NN
and  ||| S:1355 E:1359 ||| CC
observation  ||| S:1359 E:1371 ||| NNS
can  ||| S:1371 E:1375 ||| MD
help  ||| S:1375 E:1380 ||| VB
clinicians  ||| S:1380 E:1391 ||| RB
make  ||| S:1391 E:1396 ||| VB
an  ||| S:1396 E:1399 ||| DT
accurate  ||| S:1399 E:1408 ||| JJ
diagnosis ||| S:1408 E:1417 ||| NN
.  ||| S:1417 E:1419 ||| .
In  ||| S:1419 E:1422 ||| IN
recent  ||| S:1422 E:1429 ||| JJ
years ||| S:1429 E:1434 ||| NNS
,  ||| S:1434 E:1436 ||| ,
the  ||| S:1436 E:1440 ||| DT
vastly  ||| S:1440 E:1447 ||| JJ
improved  ||| S:1447 E:1456 ||| JJ
understanding  ||| S:1456 E:1470 ||| NN
of  ||| S:1470 E:1473 ||| IN
the  ||| S:1473 E:1477 ||| DT
mechanism  ||| S:1477 E:1487 ||| NN
underlying  ||| S:1487 E:1498 ||| VBG
fibromyalgia  ||| S:1498 E:1511 ||| NNS
and  ||| S:1511 E:1515 ||| CC
the  ||| S:1515 E:1519 ||| DT
related  ||| S:1519 E:1527 ||| JJ
spectrum  ||| S:1527 E:1536 ||| NN
of  ||| S:1536 E:1539 ||| IN
diseases  ||| S:1539 E:1548 ||| NNS
has  ||| S:1548 E:1552 ||| VBZ
fostered  ||| S:1552 E:1561 ||| VBN
rapid  ||| S:1561 E:1567 ||| JJ
advances  ||| S:1567 E:1576 ||| NNS
in  ||| S:1576 E:1579 ||| IN
the  ||| S:1579 E:1583 ||| DT
therapy  ||| S:1583 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
these  ||| S:1594 E:1600 ||| DT
chronic  ||| S:1600 E:1608 ||| JJ
pain  ||| S:1608 E:1613 ||| NN
disorders  ||| S:1613 E:1623 ||| NNS
by  ||| S:1623 E:1626 ||| IN
both  ||| S:1626 E:1631 ||| DT
pharmacologic  ||| S:1631 E:1645 ||| NN
and  ||| S:1645 E:1649 ||| CC
nonpharmacologic  ||| S:1649 E:1666 ||| JJ
interventions ||| S:1666 E:1679 ||| NNS
.  ||| S:1679 E:1681 ||| .
